Original Investigation
Very Late Scaffold Thrombosis: Intracoronary Imaging and Histopathological and Spectroscopic Findings

https://doi.org/10.1016/j.jacc.2015.08.853Get rights and content
Under an Elsevier user license
open archive

Abstract

Background

Bioresorbable scaffolds provide transient lumen support followed by complete resorption.

Objectives

This study examined whether very late scaffold thrombosis (VLScT) occurs when resorption is presumed to be nearly complete.

Methods

Patients with VLScT at 3 tertiary care centers underwent thrombus aspiration followed by optical coherence tomography (OCT). Thrombus aspirates were analyzed by histopathological and spectroscopic examination.

Results

Between March 2014 and February 2015, 4 patients presented with VLScT at 44 (case 1), 19 (cases 2 and 4), and 21 (case 3) months, respectively, after implantation of an Absorb Bioresorbable Vascular Scaffold 1.1 (Abbott Laboratories, Abbott Park, Illinois). At the time of VLScT, all patients were taking low-dose aspirin, and 2 patients were also taking prasugrel. OCT showed malapposed scaffold struts surrounded by thrombus in 7.1%, 9.0%, and 8.9% of struts in cases 1, 2, and 4, respectively. Scaffold discontinuity with struts in the lumen center was the cause of malapposition in cases 2 and 4. Uncovered scaffold struts with superimposed thrombus were the predominant findings in case 3. OCT percent area stenosis at the time of VLScT was high in case 1 (74.8%) and case 2 (70.9%) without evidence of excessive neointimal hyperplasia. Spectroscopic thrombus aspirate analysis showed persistence of intracoronary polymer fragments in case 1.

Conclusions

VLScT may occur at advanced stages of scaffold resorption. Potential mechanisms specific for VLScT include scaffold discontinuity and restenosis during the resorption process, which appear delayed in humans; these findings suggest an extended period of vulnerability for thrombotic events.

Key Words

bioresorbable scaffold
coronary artery disease
optical coherence tomography
thrombosis

Abbreviations and Acronyms

BVS
bioresorbable vascular scaffold
CAD
coronary artery disease
DAPT
dual antiplatelet therapy
DES
drug-eluting stent(s)
IR
infrared
LCX
left circumflex artery
OCT
optical coherence tomography
RVD
reference vessel diameter
VLScT
very late scaffold thrombosis
VLST
very late stent thrombosis

Cited by (0)

This study was supported by institutional grants and a grant from the Swiss National Science Foundation (33CM30_140336 I 1). Dr. Räber is on the advisory board of Abott Vascular; and received speaker fees from St. Jude Medical. Drs. Windecker, Sabaté, and Serruys have received research grants and speaker fees from Abbott Vascular. Dr. Windecker has received speaker’s honoraria from AstraZeneca, Eli Lilly, Boston Scientific, Biosensors, Biotronik, Medtronic, and Edwards; and has received grants to the institution from Abbott Vascular, Boston Scientific, Biosensors, Biotronik, Medtronic, and Edwards. Dr. Onuma is on the advisory board of Abbott Vascular. Dr. Freixa is a proctor for St. Jude Medical. Dr. Eberli has received institutional grants from Abbott Vascular, Biotronik, and Terumo. Dr. Joner has received institutional grants from Abbott Vascular, Biosensors, Biotronic, Boston Scientific, CeloNova, Medtronic, MicroPort, Stentys, OrbusNeich Medical, SINO Medical Technology, Terumo, and W.L. Gore. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Listen to this manuscript's audio summary by JACC Editor-in-Chief Dr. Valentin Fuster.